目的 探討血必凈注射液聯(lián)合利巴韋林治療重癥病毒性肺炎的臨床療效。方法 納入2021年1月—2023年12月安徽理工大學第一附屬醫(yī)院ICU診斷為重癥病毒性肺炎患者86例，采用計算機生成隨機數(shù)字表，將患者按照入組順序隨機分為對照組38例和治療組36例。對照組靜脈滴注利巴韋林注射液，0.5 g加入0.9%氯化鈉溶液250 mL，1次/d。治療組在對照組治療基礎上靜脈滴注血必凈注射液，50 mL/次，2次/d。兩組均連續(xù)治療2周。觀察兩組臨床療效、一般臨床指標、肺部影像學改善情況、實驗室相關指標。結果 治療后，治療組和對照組總有效率分別是91.67%、81.58%，兩組比較差異無統(tǒng)計學意義。與對照組相比，治療組臨床恢復時間、退熱時間、平均住院時間均顯著短于對照組，而肺部影像學改善率、臨床康復率顯著高于對照組（P＜0.05）。治療后，兩組淋巴細胞、C反應蛋白（CRP）、降鈣素原、肌酸激酶MB（CK-MB）水平均較同組治療前顯著降低（P＜0.05）；治療后，治療組淋巴細胞、CRP、降鈣素原、CK-MB水平低于對照組（P＜0.05）。結論 血必凈注射液聯(lián)合利巴韋林治療重癥病毒性肺炎具有顯著療效，能夠有效改善患者的肺部炎癥反應，縮短臨床癥狀恢復時間及住院時間，加快康復進程，安全性較好。

Objective To investigate the clinical effect of Xuebijing Injection combined with ribavirn in treatment of severe viral pneumonia. Methods A total of 86 patients diagnosed with severe viral pneumonia in the ICU of the First Affiliated Hospital of Anhui University of Science and Technology from January 2021 to December 2023 were included. A computer-generated random number table was used to randomly divide the patients into control group (38 cases) and treatment group (36 cases) according to the order of admission. Patients in the control group were iv administered with Ribavirn Injection, 0.5 g was added to 0.9% sodium chloride solution 250 mL, once daily. Patients in the treatment group were iv administered with Xuebijing Injection on the basis of the control group, 50 mL/time, twice daily. Both groups were treated continuously for 2 weeks. The clinical efficacy, general clinical indexes, lung imaging improvement and laboratory related indexes of the two groups were observed. Results After treatment, the total effective rate of the treatment group and control group was 91.67% and 81.58%, respectively, and there was no statistical significance between two groups. Compared with control group, the clinical recovery time, fever remission time and average hospital stay in treatment group were significantly shorter than those in the control group, but the lung imaging improvement rate and clinical recovery rate was significantly higher than those in control group (P < 0.05). After treatment, the levels of lymphocyte, C-reactive protein (CRP), procalcitonin and creatine kinase MB (CK-MB) in two groups were significantly decreased compared with before treatment (P < 0.05). After treatment, the levels of lymphocyte, CRP, procalcitonin and CK-MB in treatment group were lower than those in control group (P < 0.05). Conclusion Xuebijing Injection combined with ribavirn has significant efficacy in treatment of severe viral pneumonia, and can effectively improve the pulmonary inflammatory response of patients, shorten the recovery time of clinical symptoms and hospital stay, accelerate the rehabilitation process, which has good safety.

R974